COMP <GO>
OKUR vs PMVP // FREE CASH FLOW YIELD
OnKure Therapeutics Inc. (Class A) (NASDAQ) VS. PMV Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: OKUR 1
— PMVP 1
■ METRIC PARITY
LAST: $2.59 (-1.14%) • MKT CAP: $104.9M
fcf-yield
—
LAST: $1.37 (+4.58%) • MKT CAP: $103.5M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OKUR VS. PMVP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OKUR | PMVP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.3 | 50.8 | -1.50 | PMVP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $104.9M | $103.5M | $1.4M | OKUR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OKUR REV | PMVP REV | OKUR GROSS % | PMVP GROSS % | OKUR FCF | PMVP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $176.3M | $241.4M | — | — | -$51.9M | -$73.6M |
| FY 2024 | $152.3M | $239.3M | — | — | -$51.2M | -$51.9M |
| FY 2023 | $103.4M | $224.4M | — | — | -$34.5M | -$55.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OKUR // BETA —
PMVP // BETA —